Long Read Sequencing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Instruments, Consumables, Services), By Technology (Single-Molecule Real-Time Sequencing (SMRT), Nanopore Sequencing, Others), By Workflow (Pre-Sequencing, Sequencing, Data Analysis), By Application (Oncology, Infectious Diseases, Rare Diseases, Genetic Disorders, Metabolic Disorders, Others), By End User (Hospitals & Clinics, Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Long Read Sequencing Market was valued at USD 610.27 million in 2024 and is expected to reach USD 1847.24 million by 2030 with a CAGR of 20.28% during the forecast period. The global market for Long Read Sequencing is experiencing significant growth, driven by growing occurrences of genetic disorders, growing government support for R&D activities and extensive development in technology are fueling the growth of the market. Long-read sequencing, also known as third-generation sequencing, is a DNA sequencing technique which is being researched. It can determine the nucleotide sequence of long sequences of DNA ranging between 10,000 and 100,000 base pairs at a time. This technology eliminates the need to cut up and then amplify DNA which is usually needed in other DNA sequencing methods. The other factors supporting the market’s growth are, rise in R&D activities, growing number of patients with genetic diseases including cancer, increasing number of clinical trials, rising popularity of personalized medicine, increasing acceptance of modern approaches for medical diagnostics, rising utilization of sequence analysis methodologies in medical institutes for academic purposes, rise in world population, growing adoption of inorganic growth strategies, and immense potential for emerging submarkets.

Key Market Drivers

Population-Scale Genomics Fuels Demand for Long Reads

Long-read sequencing is being pulled into the mainstream by population-scale genomics and precision-medicine programs that need complete, ancestry-inclusive views of the genome, including structural variants, repeat expansions, and complex loci that short reads routinely miss. Costs have fallen dramatically, removing a major adoption barrier: the U.S. National Human Genome Research Institute (NHGRI) documents the collapse in per-genome costs over the past decade, which has enabled very large sequencing cohorts and downstream technology adoption, including long-read platforms where they add unique value.

The scale of these cohorts is unprecedented. NIH’s All of Us program announced in 2025 that it now provides researchers access to >414,000 whole-genome sequences, with a mandate to represent diverse ancestries so that biomarkers and risk models work equitably. Such breadth exposes variants in hard-to-map regions and boosts demand for long reads to resolve them. In parallel, the Human Pangenome Reference Consortium (HPRC) released a first draft pangenome comprising 47 phased diploid assemblies (94 haplotypes) built with long-read and long-range technologies; the companion paper shows ~119 Mb of added euchromatic sequence and >90 Mb of structural-variation-derived sequence relative to GRCh38—precisely the variation types where long reads are indispensable.

Public-Health Genomics and Preparedness Prioritize Long-Read Capabilities

Since COVID-19, governments have made genomic surveillance a core pillar of health security, and long-read sequencing is strategically attractive because it can characterize whole genomes (DNA or RNA), structural changes, and methylation/epigenetics in a single workflow and, crucially, do so rapidly and in decentralized settings. The WHO Global Genomic Surveillance Strategy sets an objective that by 2032 all 194 Member States have timely access to sequencing for pathogens with epidemic potential—an explicit scale-up that catalyzes procurement, training, and platform deployment. In the U.S., CDC’s Advanced Molecular Detection (AMD) program invests nationally in sequencing infrastructure and workforce development for public-health labs, while traveler-based and wastewater surveillance programs have screened hundreds of thousands of samples to detect variants early.

In Europe, national health systems are moving from pilot to implementation. The U.K. announced collaborations among Genomics England, UK Biobank, NHS England and Oxford Nanopore to roll out rapid long-read workflows across up to 30 NHS sites for severe respiratory infections, with the aim of identifying pathogens and resistance markers within ~6 hours—linking sequencing results to treatment decisions and national situational awareness. Such whole-of-government efforts create sustained, non-pandemic demand for portable, fieldable long-read devices and for high-throughput long-read capacity in reference labs.

Download Free Sample Report

Key Market Challenges

Clinical-Grade Validation, Throughput, and Cost-of-Quality

To move from research to routine care, long-read assays must meet exacting regulatory and payer expectations for analytical validity, clinical validity, and clinical utility—often across multiple jurisdictions. In the U.S., the FDA has formal frameworks for genomic tests (e.g., use of validated public variant databases and evidentiary requirements). While these enable submissions, they also raise the bar on precision, reproducibility, and comparability versus entrenched short-read workflows. Building the needed evidence—prospective studies, orthogonal confirmations, and robust QC for ultra-long molecules—adds time and expense.

Operationally, labs face throughput and cost-of-quality tradeoffs. Long reads uniquely resolve complex variation, but maintaining high per-sample yield and accuracy (particularly for small variants) can require higher coverage, optimized library prep, and stringent run QC. That increases reagent usage, compute time, and bioinformatics oversight, impacting cost-per-diagnosis in budget-constrained health systems. Even with NHGRI-tracked cost declines at the industry level, achieving clinical-grade long-read performance with consistent turnaround times remains challenging, particularly for medium-volume hospital labs that lack economies of scale.

Data Pipelines, Pangenome Adoption, and Interoperability at Scale

Long reads shine on complex regions—but that strength depends on robust analysis pipelines that can assemble, align, and interpret reads against graph/pangenome references, not just linear GRCh38. The HPRC and related initiatives are rapidly improving references; nonetheless, widespread clinical adoption requires toolchains that are validated, user-friendly, and interoperable across labs and countries. Without that, variant calls (especially complex SVs and tandem repeats) can vary by pipeline, complicated reporting and payer acceptance.

Data management is another hurdle. Long-read datasets are large, often include native-base modification (epigenetic) signals, and can require assembly-level analyses. Public programs are building models.e.g., NIH’s All of Us now enables >414k WGS for thousands of researchers—but most hospital systems lack the storage, compute elasticity, and DevOps support to run long-read workflows at scale with full auditability and PHI protections. Harmonizing outputs with public-health pipelines (CDC/AMD) or EU repositories also raises cross-border data-transfer and governance issues.

Key Market Trends

Hybrid & Pangenome-Aware Analysis Becomes Routine

A defining trend is the convergence of hybrid sequencing (short + long reads) with pangenome-aware analysis. Clinicians and researchers increasingly pair short reads for high small-variant precision with long reads for phasing, SVs, repeats, and complex loci, then interpret results against graph-based references that better reflect human diversity. The NIH-funded HPRC and its 2023 Nature paper quantified the added sequence and gene duplications uncovered by pangenome assemblies, illustrating why moving beyond GRCh38 improves sensitivity and reduces reference bias—especially for under-represented ancestries emphasized by NIH’s All of Us expansion to >414k genomes.

Practically, that means clinical pipelines are evolving: SV callers, repeat-expansion detectors, and phasing tools are being validated in hybrid contexts; tumor boards and rare-disease programs are piloting combined reports that integrate CNVs, repeats, methylation, and phased haplotypes. As pangenome resources mature, expect guideline bodies to reference graph-aware methods for certain loci (e.g., HLA/KIR, SMN1/2, pharmacogenes) where linear references struggle. Over time, this hybrid/pangenome model standardizes the use of long reads without forcing labs to abandon well-established short-read assets—accelerating adoption while improving equity and diagnostic yield.

From Bench to Bedside: Targeted Clinical Assays and Real-Time Field Sequencing

Two complementary currents are shaping commercialization. First, targeted clinical long-read assays are emerging for indications where the technology’s advantages are decisive: repeat-expansion disorders, complex SVs in neurodevelopmental disease, pharmacogenomic star allele resolution, BCR-ABL and HLA typing, and minimal-residual disease phasing. Peer-reviewed work and registered studies are testing long-read panels for “challenging diagnoses” where short reads underperform—an on-ramp to broader clinical use as evidence accrues.

Second, real-time field sequencing is moving into national care pathways. The U.K. is deploying rapid long-read workflows across up to 30 NHS sites to identify respiratory pathogens and resistance markers within ~6 hours, integrating results into treatment decisions and national early-warning systems; similar preparedness investments can be seen in U.S. CDC AMD and WHO’s surveillance roadmap. These programs institutionalize portable, rapid long-read sequencing for infection control and outbreak response, creating recurring demand beyond pandemic spikes. As procurement frameworks, training, and reimbursement solidify, expect knock-on effects: hospital labs adopting long reads for oncology/rare-disease panels, public-health labs standardizing AMR/epidemiology workflows, and reference centers offering methylation + sequence assays from a single DNA prep.

Segmental Insights

Component Insights

Based on Component, the consumables segment holds the largest market share under the component category. Consumables include reagents, sample preparation kits, flow cells, cartridges, and other recurring supplies essential for every sequencing run. Unlike instruments, which are one-time or infrequent capital investments, consumables are required on a continuous basis for each experiment or sequencing project, creating a recurring revenue stream for manufacturers. This makes them the most dominant contributor to overall market revenues. A major factor driving the dominance of consumables is the growing number of sequencing studies and genomic research projects worldwide, which require large volumes of consumables for sample preparation, library construction, and sequencing reactions. For example, the U.S. National Institutes of Health (NIH) allocated over USD 3.1 billion to genomics research in 2020, much of which translates into demand for consumables. Similarly, large-scale projects such as the 100,000 Genomes Project in the UK and the GenomeAsia 100K initiative rely heavily on consumables to process thousands of DNA samples. As these projects expand, the demand for sequencing consumables is expected to outpace instruments and services.

Download Free Sample Report

Regional Insights

Based on the region, North America holds the largest market share, primarily due to its advanced healthcare infrastructure, strong presence of genomic research institutes, and significant government funding for precision medicine and genomics. The United States has been at the forefront of sequencing innovations, driven by initiatives such as the All of Us Research Program led by the National Institutes of Health (NIH), which aims to collect genetic and health data from over one million people to advance personalized healthcare. According to the NIH, the U.S. government invested more than USD 3.1 billion in genomics research in 2022, highlighting the scale of support for projects that directly use or benefit from sequencing technologies, including long read sequencing.

Additionally, the presence of leading sequencing technology developers and biotechnology companies in the U.S. and Canada has further strengthened the region’s dominance. These firms have actively partnered with academic and clinical research institutions to develop long read sequencing applications for oncology, rare disease detection, and structural variation analysis. Moreover, favorable reimbursement policies and increasing adoption of genomic sequencing in clinical settings have accelerated market penetration. With a well-established regulatory environment, strong R&D investments, and early adoption of innovative technologies, North America is expected to maintain its leadership position in the global market.

Recent Developments

• In February 2025, Oxford Nanopore Technologies is partnering with the University of Tübingen and other European institutions to establish its sequencing technology as a first-line diagnostic tool.
• In July 2024, Oxford Nanopore Technologies and Plasmidsaurus have announced a strategic partnership aimed at advancing plasmid sequencing capabilities.
• In June 2023, Pacific Biosciences of California, Inc. and Rady Children’s Institute for Genomic Medicine (RCIGM) announced a collaborative study focused on identifying potential disease-causing genetic variants and improving diagnostic success rates in rare disease cases.

Key Market Players

• Agilent Technologies, Inc.
• BGI Group
• Bionano Genomics, Inc.
• Circulomics Inc
• Oxford Nanopore Technologies plc
• Longas Technologies Pty Ltd
• Novogene Co., Ltd.
• Illumina, Inc.
• F. Hoffmann-La Roche AG
• Pacific Biosciences of California, Inc.

Report Scope:

In this report, the Global Long Read Sequencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Long Read Sequencing Market, By Component:

o   Instruments

o   Consumable

o   Services

• Long Read Sequencing Market, By Technology:

o   Single-Molecule Real-Time Sequencing (SMRT)

o   Nanopore Sequencing

o   Others

• Long Read Sequencing Market, By Workflow:

o   Pre-Sequencing

o   Sequencing

o   Data Analysis

• Long Read Sequencing Market, By Application:

o   Oncology

o   Infectious Diseases

o   Rare Diseases

o   Genetic Disorders

o   Metabolic Disorders

o   Others

• Long Read Sequencing Market, By End User:

o   Hospitals & Clinics

o   Biotechnology & Pharmaceutical Companies

o   Academic & Research Institutions

o   Others

• Long Read Sequencing Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Long Read Sequencing Market.

Available Customizations:

Global Long Read Sequencing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Long Read Sequencing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]